Research Roundup

old bulbs with a smart bulb in middle

Debbie Rigby takes a look at the latest in research news relevant to pharmacy

Current and new pharmacotherapeutic approaches for glaucoma

Glaucoma is the leading cause of irreversible blindness. This review outlines current topical therapies for glaucoma, in addition to new medications under trials. Current medication options include the following classes: alpha-adrenergic agonists, beta-adrenergic antagonists, cholinergic agonists, carbonic anhydrase inhibitors, and prostaglandin analogues. Noncompliance, cost, side effects, and intraocular pressure fluctuation are the major problems with topical therapy.

Expert Opinion on Pharmacotherapy, 2020.


Optimal management of severe symptomatic gastroesophageal reflux disease

Gastroesophageal reflux disease is a common disorder, and empirical proton pump inhibitor (PPI) treatment is often the first step of management; however, up to 40% of patients remain symptomatic despite PPI treatment. This review summarises current diagnostic approaches and critically evaluates the evidence for the efficacy of available treatments.

Journal of Internal Medicine 2020.


Statin exposure and the risk of dementia in individuals with hypercholesterolaemia

In this retrospective cohort study with a median of 11.7 years follow-up, patient taking a statin had a 30% lower risk of overall dementia and Alzheimer’s disease and related dementia in women and men, and a lower risk of other types of dementia in women, than subjects who were not exposed to statins.

Journal of Internal Medicine 2020.


Deprescribing in older people

Deprescribing is the process of discontinuing drugs that are either potentially harmful or no longer required. It can be achieved in older people and may be associated with improved health outcomes without long-term adverse effects. The risk of drug withdrawal effects can often be mitigated by carefully monitoring and gradually tapering the dose. Deprescribing should ideally be a shared decision-making process between the patient and the prescriber.

Aust Prescr 2020;43:114-20.

Previous ‘No system’ for ED prescription pads
Next Some community pharmacies reporting 90% downturn

NOTICE: It can sometimes take awhile for comment submissions to go through, please be patient.

No Comment

Leave a reply